(JAZZ) Jazz Pharmaceuticals - Ratings and Ratios
Oxybate,Sleep,Seizure,Cancer,HEMATOLOGY
JAZZ EPS (Earnings per Share)
JAZZ Revenue
Description: JAZZ Jazz Pharmaceuticals
Jazz Pharmaceuticals PLC is a pharmaceutical company that develops and commercializes treatments for various serious conditions, including narcolepsy, seizures, leukemia, and lung cancer. The companys product portfolio includes Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos, which are used to treat a range of diseases. Jazz Pharmaceuticals has a strong pipeline of products in development, including Zanidatamab, Suvecaltamide, JZP815, JZP898, JZP441, JZP324, and JZP150, which are being tested for various indications.
From a financial perspective, Jazz Pharmaceuticals has a market capitalization of approximately $6.95 billion USD, indicating a significant presence in the pharmaceutical industry. The companys price-to-earnings ratio is around 15.61, suggesting a relatively stable valuation. Additionally, the return on equity (RoE) is 11.90%, indicating a decent return for shareholders. Key performance indicators (KPIs) to watch include revenue growth, R&D expenses as a percentage of revenue, and the progression of pipeline products through clinical trials.
The companys partnerships with other pharmaceutical companies, such as Redx Pharma plc, Autifony Therapeutics Limited, and Zymeworks Inc., demonstrate its commitment to collaboration and innovation. With a diverse portfolio of products and a strong pipeline, Jazz Pharmaceuticals is well-positioned for future growth. Key metrics to monitor include the commercial success of its products, particularly Xywav and Epidiolex, as well as the advancement of its pipeline products, such as Zanidatamab and Suvecaltamide.
To further evaluate Jazz Pharmaceuticals prospects, it is essential to analyze its revenue breakdown by product, geographic region, and customer segment. Additionally, assessing the companys cash flow generation, debt levels, and dividend policy can provide insights into its financial health and ability to invest in R&D. By closely monitoring these KPIs, investors can gain a deeper understanding of the companys strengths and weaknesses, ultimately informing their investment decisions.
JAZZ Stock Overview
| Market Cap in USD | 7,749m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2007-06-01 |
JAZZ Stock Ratings
| Growth Rating | -19.3% |
| Fundamental | 62.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -0.45% |
| Analyst Rating | 4.44 of 5 |
JAZZ Dividends
Currently no dividends paidJAZZ Growth Ratios
| Growth Correlation 3m | 88.9% |
| Growth Correlation 12m | -4.1% |
| Growth Correlation 5y | -78.1% |
| CAGR 5y | -5.12% |
| CAGR/Max DD 3y | -0.13 |
| CAGR/Mean DD 3y | -0.22 |
| Sharpe Ratio 12m | 1.22 |
| Alpha | 4.01 |
| Beta | 0.561 |
| Volatility | 27.15% |
| Current Volume | 559.9k |
| Average Volume 20d | 675.6k |
| Stop Loss | 122.2 (-3.1%) |
| Signal | -0.90 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (-404.8m TTM) > 0 and > 6% of Revenue (6% = 245.2m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA 2.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 31.30% (prev 54.37%; Δ -23.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 1.32b > Net Income -404.8m (YES >=105%, WARN >=100%) |
| Net Debt (4.24b) to EBITDA (421.9m) ratio: 10.06 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (61.2m) change vs 12m ago -12.11% (target <= -2.0% for YES) |
| Gross Margin 84.75% (prev 85.52%; Δ -0.77pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 36.64% (prev 34.41%; Δ 2.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.09 (EBITDA TTM 421.9m / Interest Expense TTM 229.7m) >= 6 (WARN >= 3) |
Altman Z'' 0.63
| (A) 0.12 = (Total Current Assets 3.35b - Total Current Liabilities 2.07b) / Total Assets 10.94b |
| (B) 0.02 = Retained Earnings (Balance) 191.3m / Total Assets 10.94b |
| (C) -0.02 = EBIT TTM -250.0m / Avg Total Assets 11.15b |
| (D) -0.04 = Book Value of Equity -294.4m / Total Liabilities 7.24b |
| Total Rating: 0.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 62.32
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 11.04% = 5.0 |
| 3. FCF Margin 30.96% = 7.50 |
| 4. Debt/Equity 1.45 = 1.53 |
| 5. Debt/Ebitda 12.75 = -2.50 |
| 6. ROIC - WACC data missing |
| 7. RoE -10.03% = -1.67 |
| 8. Rev. Trend 44.55% = 2.23 |
| 9. Rev. CAGR 3.93% = 0.49 |
| 10. EPS Trend -10.37% = -0.26 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of JAZZ shares?
Over the past week, the price has changed by -2.58%, over one month by +11.32%, over three months by +14.38% and over the past year by +18.52%.
Is Jazz Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JAZZ is around 118.52 USD . This means that JAZZ is currently overvalued and has a potential downside of -6.06%.
Is JAZZ a buy, sell or hold?
- Strong Buy: 10
- Buy: 6
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the JAZZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 186.5 | 47.8% |
| Analysts Target Price | 186.5 | 47.8% |
| ValueRay Target Price | 131.7 | 4.4% |
Last update: 2025-09-03 04:41
JAZZ Fundamental Data Overview
CCE Cash And Equivalents = 1.67b USD (Cash And Short Term Investments, last quarter)
P/E Forward = 11.9332
P/S = 1.8962
P/B = 2.0908
P/EG = 10.4632
Beta = 0.339
Revenue TTM = 4.09b USD
EBIT TTM = -250.0m USD
EBITDA TTM = 421.9m USD
Long Term Debt = 4.34b USD (from longTermDebt, last quarter)
Short Term Debt = 1.04b USD (from shortTermDebt, last quarter)
Debt = 5.38b USD (Calculated: Short Term 1.04b + Long Term 4.34b)
Net Debt = 4.24b USD (from netDebt column, last quarter)
Enterprise Value = 11.46b USD (7.75b + Debt 5.38b - CCE 1.67b)
Interest Coverage Ratio = -1.09 (Ebit TTM -250.0m / Interest Expense TTM 229.7m)
FCF Yield = 11.04% (FCF TTM 1.27b / Enterprise Value 11.46b)
FCF Margin = 30.96% (FCF TTM 1.27b / Revenue TTM 4.09b)
Net Margin = -9.91% (Net Income TTM -404.8m / Revenue TTM 4.09b)
Gross Margin = 84.75% ((Revenue TTM 4.09b - Cost of Revenue TTM 623.3m) / Revenue TTM)
Tobins Q-Ratio = -38.92 (set to none) (Enterprise Value 11.46b / Book Value Of Equity -294.4m)
Interest Expense / Debt = 1.23% (Interest Expense 66.1m / Debt 5.38b)
Taxrate = -19.44% (set to none) (-91.4m / 470.4m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.62 (Total Current Assets 3.35b / Total Current Liabilities 2.07b)
Debt / Equity = 1.45 (Debt 5.38b / last Quarter total Stockholder Equity 3.71b)
Debt / EBITDA = 12.75 (Net Debt 4.24b / EBITDA 421.9m)
Debt / FCF = 4.25 (Debt 5.38b / FCF TTM 1.27b)
Total Stockholder Equity = 4.04b (last 4 quarters mean)
RoA = -3.70% (Net Income -404.8m, Total Assets 10.94b )
RoE = -10.03% (Net Income TTM -404.8m / Total Stockholder Equity 4.04b)
RoCE = -2.99% (Ebit -250.0m / (Equity 4.04b + L.T.Debt 4.34b))
RoIC = unknown (NOPAT none, Invested Capital 9.77b, Ebit -250.0m)
WACC = unknown (E(7.75b)/V(13.13b) * Re(8.08%)) + (D(5.38b)/V(13.13b) * Rd(1.23%) * (1-Tc(none)))
Shares Correlation 3-Years: -51.52 | Cagr: -0.23%
Discount Rate = 8.08% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 81.29% ; FCFE base≈1.18b ; Y1≈1.45b ; Y5≈2.46b
Fair Price DCF = 684.8 (DCF Value 41.54b / Shares Outstanding 60.7m; 5y FCF grow 24.66% → 3.0% )
Revenue Correlation: 44.55 | Revenue CAGR: 3.93%
Rev Growth-of-Growth: -0.50
EPS Correlation: -10.37 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -176.2
Additional Sources for JAZZ Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle